Phase 3 Readout
BIIB: Phase 3 Topline: A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy an
June 1, 2027 · felzartamab. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 1, 2027
- Company
- BIOGEN INC. (BIIB)
- Drug
- felzartamab
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy an
- Company
- BIOGEN INC. (BIIB)
- Drug
- felzartamab
- Indication
- Antibody-mediated Rejection